RedChip Weekly Newsletter

Immuron Ltd. (NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of many gut mediated pathogens, on Wednesday provided shareholders with an update on the company’s cooperative research and development agreements with the U.S. Department of Defense.

Here are the highlights:

Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completed
Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated NHPs compared to placebo.
A preventative treatment that protects against enteric diseases, specifically Shigella, is a high priority objective for the U.S. Army

The Backstory: The Department of Defense commissioned several studies to characterize the antibodies within Travelan®, the company’s commercially available flagship over-the-counter gastrointestinal and digestive health supplement. The aim was to conduct trials to determine the product’s effectiveness in neutralizing pathogenic gastrointestinal bacterial infections as a preventative treatment for U.S. military personnel and civilians stationed or traveling in locations where such infections may be debilitating.

The U.S. Armed Forces Research Institute of Medical Sciences (AFRIMS), an overseas laboratory of the Walter Reed Army Institute of Research (WRAIR), located in Bangkok, Thailand, conducted the study that evaluated the therapeutic potential of Travelan® in a non-human primate (NHP) preclinical challenge model that closely mimics the disease seen in humans. The study was performed in collaboration with the Department of Enteric Diseases and the Department of Veterinary Medicine, AFRIMS, and the Department of Enteric Infections, Bacterial Diseases Branch, WRAIR.

The placebo-controlled study was carried out in 12 NHPs segregated into 2 groups: a Travelan® treatment cohort of 8 and a placebo cohort of 4, which were treated with either Travelan® or placebo respectively twice daily for a total of 12 doses over a 6-day period. The animals received treatment for 3-days prior to oral challenge with ~3 x 109 viable Shigella flexneri strain 2a organisms. All (4 of 4 - 100%) placebo-treated animals displayed acute dysentery symptoms within 24 – 36 hours of Shigella flexneri 2a challenge. A single (1 of 8 – 12.5%) of the Travelan®-treated cohort displayed dysentery symptoms at this time point. The remaining individuals (7 of 8 – 87.5%) in the Travelan® treatment cohort remained symptom-free to 4-days post Shigella flexneri 2a challenge. Once the treatment period was concluded a second individual in the Travelan® treatment group developed symptoms (2 of 8 - 25%).

Key Quote: “Travelan® was designed to target selected surface antigens from the most common strains of Enterotoxigenic E. coli (ETEC), bacteria which play a dominant and causative role in traveler’s diarrhea. Previous studies found several of these antigens are shared with bacillary dysentery-causing organisms such as Shigella species. The work completed at AFRIMS highlighted for the first time that in a preclinical NHP challenge model of shigellosis (also known as bacillary dysentery), Travelan® protected 75% of the animals from clinical bacillary dysentery. All the placebo-treated animals displayed classic dysentery symptoms after challenge with a virulent strain of Shigella sp. It is also very interesting to note the second case of dysentery in the Travelan® cohort developed once the treatment terminated.” Dr. Jerry Kanellos, CEO of Immuron

Disclosure

Immuron Ltd. (IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for 12 months of investor awareness services.

Read 516 words

eMARINE Global (OTC: EMRN), a leading provider of information and communications technology for the maritime industry, is pleased to announce the extension and expansion of its maintenance contract with the Republic of Korea Navy (ROK Navy) for work through 2019.

The Backstory: eMARINE Global has been servicing the ROK Navy continuously for nine years, providing routine, preventive and emergency maintenance, as well as chart updates for the electronic charts display and information systems (ECDIS) onboard Korean naval vessels. The latest contract extends this relationship and expands it to more than 213 vessels. The contract is valued at approximately US$1.4 million.

Founded in 2001 and based in South Korea, eMARINE Global is working with a growing base of marquee customers to achieve maritime ICT convergence through fully integrated products and services, offering state-of-the-art e-navigation, marine Internet of Things (IoT), and marine big data solutions, primarily in Korea with near-term expansion into U.S. and Chinese markets. In addition to the ROK Navy, eMARINE Global’s customer base includes Hyundai Heavy Industries, Samsung Heavy Industries, and the Korea Coast Guard.

Key Quote: “The continuation of our work with the ROK Navy is a strong testament to the quality of our product and service offerings, and we take great pride in our contribution to the safety and security of the ROK. We currently maintain 90% market share of the Electronic Chart Display and Information System (ECDIS) business from the Korean Navy and Coast Guard and plan to leverage this success as we seek to expand regionally and globally.” Ung Gyu Kim, Chairman and CEO of eMARINE Global

Disclosure

eMARINE Global (OTC: EMRN) is a client of RedChip Companies. RedChip Companies, Inc. owns 613,000 shares of EMRN common stock.

Read 263 words

GSRX Industries (OTCQB: GSRX) announced Wednesday that its wholly-owned subsidiary, Green Spirit Mendocino, LLC, d/b/a The Green Room, a medicinal and adult-use cannabis retailer in Point Arena, California (“The Green Room”), is the only cannabis dispensary in Mendocino County which stocks and sells Dragonglass Flake and Bake™ (“Dragonglass”). Currently available at select dispensaries in San Francisco, the exclusive agreement with The Green Room marks the first time the product will be available outside the Bay Area.

The Backstory: Dragonglass is a sublingual/edible flake made using superfood, and is based on a proprietary, patent-pending method of producing water-based edibles that are free of sugar, fat, alcohol, and synthetics. GSRX believes that Dragonglass is a unique product in a market flooded with sugar-based and high-calorie products, and demand for the product has remained high since its introduction in 2017. Available in new, California-compliant packaging, Dragonglass is sold in 100mg THC and 100mg CBD versions. Dragonglass is manufactured by Spirulinex, LLC, a majority-owned subsidiary of GSRX.

Headquartered in San Francisco, Spirulinex extracts and processes concentrates using non-volatile methods, then processes and formulates products for adult consumers. Spirulinex has developed all-natural, proprietary methods of suspending cannabinoids in water to create aqueous solutions, thereby eliminating the need to use oils, butter or synthetic lipids. Spirulinex offers cannabinoid products for which scientific dosage recommendations are included for consistency and quality assurance. Spirulinex has a robust patent portfolio, and continues to aggressively pursue protection for its innovations.

Located in Mendocino County’s Point Arena, The Green Room has experienced a record increase in sales since GSRX acquired the dispensary in late spring. The Company recently reported average daily sales during the second quarter increased 161%, as compared to average daily sales during the first quarter of 2018 (Green Room Sales Increase).

Disclosure

GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services and 50,000 shares for investor awareness services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.

Read 294 words

Days after casting doubt on Canadian marijuana producer Cronos Group (NASDAQ: CRON), short-seller Citron Research is now betting that rival Tilray (NASDAQ: TLRY) is destined to fall. But Tilray stock, Cronos stock and other marijuana stocks continue to rally. In fact, Tilray is up more than 50% since we mentioned it in last week’s newsletter.

While a case can be made for short-term overvaluation of stocks like Tilray, the robust growth sector-wide points to a very positive outlook for cannabis stocks in the quarters ahead. Investors that spend the time looking for opportunities are bound to find stocks that have lagged the most recent rallies. If the fundamentals make sense, these could provide great opportunities to own cheap shares for larger, long-term uptrends in prices for the sector.

And as prices move higher, those that sold short will most likely be forced to cover, further propelling shares higher.

Spectrum Global Solutions (OTC: SGSI), a single-source provider of end-to-end next-generation wireless and wireline network services and staffing solutions to the service provider (carrier) and corporate enterprise markets, has received over $1.1 million in new contract awards in the last 30 days.

Why It Matters: This increase in business is an industry-wide increase in demand for services and solutions associated with network upgrades. The new customer orders received by Spectrum include network audit, fiber deployment, structured cabling, fiber and small cell design services and project staffing solutions. This work has already commenced, and the revenue will begin to be realized in Q3.

Key Quote: “With these new contracts we are tracking in excess of a $32 million annual gross revenue run rate. We are increasing our profit margins on this revenue and reducing our cost of capital as we increase shareholder value.” – Roger Ponder, CEO

Disclosure

Spectrum Global Solutions (SGSI) is a client of RedChip Companies, Inc. SGSI agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.

Small-cap stocks' big run this year will keep going into year-end, according to Stifel.

The firm is optimistic about smaller companies because of their strong financial performance and the benefits they got from tax reform.

"As we move into the second half of the year, the market environment is positioned well for U.S. small cap equities to remain one of the preferred markets," global head of investment strategy Michael O'Keeffe said in a note to clients in late August. "Small business owners continue to anticipate greater sales and even better business conditions for the remainder of the year. We expect this to result in increased investment spending that ultimately leads to GDP growth."

The strategist said small companies have less exposure to international markets than companies in the S&P 500 in the event the global trade environment deteriorates.

Key Quote: "Small cap equities provide an opportunity for investors to invest in companies that generate a large portion of their revenue inside the U.S., potentially insulating them from geopolitical developments," he said. "We remain constructive on U.S. small cap equities looking forward."

Esports Entertainment Group (OTCQB:GMBL) (or the "Company"), a licensed online gambling company with a specific focus on esports wagering and 18+ gaming, is pleased to announce the signing of 193 VIE Affiliates at Gamescom 2018, the world’s largest event for computer and video games. These VIE Affiliates represent professional players, streamers and influencers that collectively reach a massive audience of esports participants around the world.

This result represents an increase of 220% over Gamescom 2017 and further signifies esports industry acceptance as the Company ramps up affiliate marketing activities in support of Vie.gg, the world’s first and most transparent esports betting exchange. As a result of the conference, the Company is in discussions with several high profile esports participants and believes further developments will be announced.

The Backstory: Esports Entertainment Group is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers bet exchange style wagering on esports events in a licensed, regulated and secure platform to the global esports audience. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multi-player mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports. The Company holds licenses to conduct online gambling and 18+ gaming on a global basis in Curacao, Kingdom of the Netherlands and the Kahnawake Gaming Commission in Canada. The Company maintains offices in Antigua, Curacao and Warsaw, Poland. Esports Entertainment common stock is listed on the OTCQB under the symbol GMBL. For more information visit www.esportsentertainmentgroup.com

Disclosure

Esports Entertainment Group, Inc. (GMBL) is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.